BDBM387815 US10294226, Compound A::US10487083, Example A::US11059823, Example A

SMILES Cc1nc2cnc3[nH]ccc3c2n1[C@H]1CC[C@H](CC#N)CC1

InChI Key

Data  15 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 4 hits for monomerid = 387815   

TargetNon-receptor tyrosine-protein kinase TYK2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50:  0.900nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK1(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: <0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK2(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50: <0.200nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent
TargetTyrosine-protein kinase JAK3(Homo sapiens (Human))
Janssen Pharmaceutica

US Patent
LigandPNGBDBM387815(US10294226, Compound A | US10487083, Example A | U...)
Affinity DataIC50:  12.4nMAssay Description:11-point dosing series were made for each compound by serially diluting 1:3 or 1:4 in DMSO, with point 12 being a DMSO control. From the serial dilut...More data for this Ligand-Target Pair
Ligand InfoPC cidPC sid
In DepthDetails US Patent